# Docetaxel in Treating Patients With Relapsed Prostate Cancer

> **NCT00482274** · PHASE2 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 3 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00482274
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Drug supplier stopped funding due to loss of study drug (docetaxel) patent.
- **Last updated:** 2017-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00482274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00482274, "Docetaxel in Treating Patients With Relapsed Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00482274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*